We also found that the efficacy of mini-GAGR in increasing Nrf2 nuclear localization and transcriptional activation was comparable with midi-GAGR and other Nrf2 activators (DMF (4) and CDDO-TFEA (45, 46)) that are already in clinical trials (DMF for multiple sclerosis, CDDO-TEFA (RTA-408) for Huntington's disease and Friederich's ataxia) (Fig. 3). This evidence concerns the gene NFE2L2 and multiple sclerosis.